Parker Institute for Cancer Immunotherapy CEO and leadership

• 20+ years of research experience in immunotherapy with strong focus on deep immune monitoring• Leading a team of scientists and researchers at the Tessa Therapeutics - Institute of Molecular and Cell Biology (IMCB) Co-lab to develop next generation T cell therapy treatments• Published more than 100 papers and chapters in peer-reviewed journals. ResearchGate link: https://www.researchgate.net/profile/John_Connolly11

- Senior executive with extensive experience in leading the business development, licensing, risk management and legal activities of therapeutic, diagnostic, and device companies- Expertise in driving evaluation and acquisition of novel immunotherapies, technologies, and biomarkers in cancer and infectious diseases- Responsible for all PCR technology outlicensing programs (300+ licensees) in Dx and life science fields, generating $100+ milllion annual royalty revenue for Hoffmann LaRoche- Directed GE Healthcare's Congressional and Medicare lobbying efforts to address CMS coverage and reimbursement determinations for in vitro diagnostic tests

Ramy Ibrahim, MD, is a recognized leader of clinical development in immunotherapy. He helped develop some of the first breakthrough treatments in the field during his tenure at Bristol-Myers Squibb and MedImmune/AstraZeneca. Dr. Ibrahim currently serves as Chief Medical Officer at PICI.

At AstraZeneca, Dr. Ibrahim was the Vice President of Clinical Development for Immuno-oncology, leading the team developing multiple immunotherapies. Molecules developed under his leadership included durvalumab (anti-PD-L1 antibody) and tremelimumab (anti-CTLA-4 antibody) both with single drug and combination therapies with a focus on registrational studies in multiple indications including lung cancer, bladder cancer and head and neck cancer.

As a member of the Bristol-Myers Squibb Immuno-oncology program, he served on the Yervoy (ipilimumab) clinical team supporting the program from early phase II through multiple global launches of the first FDA-approved immune checkpoint inhibitor. In addition, he played a key role in early development for nivolumab (PD-1), PD-L1 and CD137 antibody.

Throughout his career, Dr. Ibrahim has been involved with global cancer immunotherapy societies such as the Society of Immunotherapy for Cancer (SITC), Ludwig Institute, the Cancer Research Institute and Cancer Immunotherapy Trials Network (CITN). He is a trained medical oncologist, who conducted bench and clinical immunotherapy research at the cancer vaccine branch of the National Cancer Institute in Bethesda, MD.